SGR – Where Do We Go from Here?
As the 113
Congress winds down, it has become clear that this group of legislators will not be remembered as the one that permanently addressed the issues associated with Medicare physician payment. Read more to find out what may happen with the SGR in 2015.
Friends of Cancer Research and Brookings Institution Address Oncology Drug Development at a Conference on Clinical Cancer Research
Conference on Clinical Cancer Research brought together leaders in cancer drug
development from federal, health and regulatory agencies, academic research and
the private sector for focused discussions on critical issues surrounding the
development and regulation of cancer drugs and therapies.
ASH Pleased by Newly Released NHLBI Funding Opportunities for Stem Cell-Derived Blood Products for Therapeutic Use
The National Heart, Lung and Blood Institute (NHLBI) is now accepting applications for
Research Project Grants and
Small Business Technology Transfer Grants that will support research addressing scientific questions to enable and accelerate the use of stem cell-derived blood products as therapeutics. The application deadlines for these funding opportunities is February 15 and February 20, 2015, respectively.
Laboratory-Developed Tests and the FDA
The FDA recently indicated that it wishes to begin to provide regulatory oversight of some laboratory-developed tests. FDA is clear to indicate that it does not wish to include all tests in the regulatory process, and that it wishes to phase in this process over a period of years, starting with those tests that are most high risk. ASH is closely
reviewing this proposed guidance in order to prepare comments for submission to